Ironwood Pharmaceuticals is a leading global gastrointestinal healthcare company headquartered in Boston, Massachusetts. They are dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. Ironwood is known for their pioneering work in developing LINZESS, the US branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). They are also focused on developing apraglutide, a next-generation synthetic GLP-2 analog, for rare gastrointestinal diseases. With a patient-centered approach, Ironwood Pharmaceuticals aims to reduce the burden of GI diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals operates globally, with operations in Basel, Switzerland. They are committed to innovation in the field of GI healthcare and have a strong track record of bringing novel treatments to market. With a mission to improve the lives of patients suffering from GI diseases, Ironwood Pharmaceuticals is a trusted name in the industry.
Generated from the website